All Alport patients residing in the U.S. are encouraged to enroll today.
February 25, 2022 On February 25th, the U.S. Food and Drug Administration (FDA) announced its decision not to approve a New Drug Application for the use of bardoxolone methyl as a treatment for Alport syndrome. Bardoxolone methyl was investigated for safety and efficacy in Alport patients through the CARDINAL Study, the first-ever clinical trial […]
February 1, 2022 ASF invites you to join us for 60-minute, staff- and volunteer-moderated Direct Connect virtual meetings (held over Zoom) that provide important opportunities for patients and family members to meet others facing similar life circumstances, ask questions, identify areas of need, and help lay groundwork for future educational content. Topics will vary by […]